Related Articles
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer
FABP4 knockdown suppresses inflammation, apoptosis and extracellular matrix degradation in IL-1β-induced chondrocytes by activating PPARγ to regulate the NF-κB signaling pathway
PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports